Cited by 1,674Breast Cancer Treatment StudiesEstrogen and related hormone effectsEndometrial and Cervical Cancer Treatments

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Cuzick, Jack, Sestak, Ivana, Baum, Michael, Buzdar, Aman, Howell, Anthony, Dowsett, Mitch, Forbes, John F·2010·The Lancet Oncology

DOI 10.1016/s1470-2045(10)70257-6

Open this paper in CoChat — free account

Abstract

Background The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg), both given orally every day for 5 years, as adjuvant treatment for postmenopausal women with early-stage breast cancer. In this analysis, we assess the long-term outcomes after a median follow-up of 120 months.Methods We used a proportional hazards model to assess the primary endpoint of disease-free survival, and the secondary endpoints of time to recurrence, time to distant recurrence, incidence of new contralateral breast cancer, overall survival, and death with or without recurrence in all randomised patients (anastrozole n=3125, tamoxifen n=3116) and hormone-receptor-positive patients (anastrozole n=2618, tamoxifen n=2598). After treatment completion, we continued to collect data on fractures and serious adverse events in a masked fashion (safety population: anastrozole n=3092, tamoxifen n=3094). This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN18233230.Findings Patients were followed up for a median of 120 months (range 0-145); there were 24,522 woman-years of follow-up in the anastrozole group and 23,950 woman-years in the tamoxifen group. In the full study population, there were significant improvements in the anastrozole group compared with the tamoxifen group for disease-free survival (hazard ratio [HR] 0·91, 95% CI 0·83-0·99; p=0·04), time to recurrence (0·84, 0·75-0·93; p=0·001), and time to distant recurrence (0·87, 0·77-0·99; p=0·03). For hormone-receptor-positive patients, the results were also significantly in favour of the anastrozole group for disease-free survival (HR 0·86, 95% CI 0·78-0·95; p=0·003), time to recurrence (0·79, 0·70-0·89; p=0·0002), and time to distant recurrence (0·85, 0·73-0·98; p=0·02). In hormone-receptor-positive patients, absolute differences in time to recurrence between anastrozole and tamoxifen increased over time (2·7% at 5 years and 4·3% at 10 years) and recurrence rates remained significantly lower on anastrozole than tamoxifen after treatment completion (HR 0·81, 95% CI 0·67-0·98; p=0·03), although the carryover benefit was smaller after 8 years. There was weak evidence of fewer deaths after recurrence with anastrozole compared with tamoxifen treatment in the hormone-receptor-positive subgroup (HR 0·87, 95% CI 0·74-1·02; p=0·09), but there was little difference in overall mortality (0·95, 95% CI 0·84-1·06; p=0·4). Fractures were more frequent during active treatment in patients receiving anastrozole than those receiving tamoxifen (451 vs 351; OR 1·33, 95% CI 1·15-1·55; p<0·0001), but were similar in the post-treatment follow-up period (110 vs 112; OR 0·98, 95% CI 0·74-1·30; p=0·9). Treatment-related serious adverse events were less common in the anastrozole group than the tamoxifen group (223 anastrozole vs 369 tamoxifen; OR 0·57, 95% CI 0·48-0·69; p<0·0001), but were similar after treatment completion (66 vs 78; OR 0·84, 95% CI 0·60-1·19; p=0·3). No differences in non-breast cancer causes of death were apparent and the incidence of other cancers was similar between groups (425 vs 431) and continue to be higher with anastrozole for colorectal (66 vs 44) and lung cancer (51 vs 34), and lower for endometrial cancer (six vs 24), melanoma (eight vs 19), and ovarian cancer (17 vs 28). No new safety concerns were reported.Interpretation These data confirm the long-term superior efficacy and safety of anastrozole over tamoxifen as initial adjuvant therapy for postmenopausal women with hormone-sensitive early breast cancer.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(10)70257-6

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
(2005) · The Lancet · doi:10.1016/s0140-6736(05)66544-0 · Cited by 7,626
Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial
(2004) · JAMA · doi:10.1001/jama.291.14.1701 · Cited by 4,534
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Self-citation
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Baum, M., Budzar, A. U., Cuzick, J. M., Forbes, J., Houghton, J., Klijn, J. G. M., & Sahmoud, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09088-8 · Cited by 1,958
Self-citation
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial
Nabholtz, J., Buzdar, A. U., Pollak, M., Harwin, W. N., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 989
Self-citation
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Williams, N. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70385-6 · Cited by 918
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
Coombes, R. C., Kilburn, L., Snowdon, C. F., Paridaens, R., Coleman, R., Jones, S., Jassem, J., van de Velde, C., Delozier, T., Álvarez, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60200-1 · Cited by 901
Self-citation

Show all 27 references

Sorted by citations

Items 501–600 of 1,000

Adherence to oral endocrine treatments in women with breast cancer: can it be improved?
Doggrell, S. A. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1578-z · Cited by 34
Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer
Nabholtz, J., Mouret‐Reynier, M., Durando, X., Praagh, I. V., Al‐Sukhun, S., Ferrière, J.-P., & Chollet, P. J. M. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902953738 · Cited by 33
Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy
Montemurro, F., & Aglietta, M. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0033 · Cited by 33
Aromatase Inhibitor–Associated Arthralgias
Chlebowski, R. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3270 · Cited by 33
The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines
Shen, L., Li, Z., Shen, S., Niu, X., Yu, Y., Li, Z., Liao, M., Chen, Z., & Lu, S. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.08.012 · Cited by 32
Caring for the Breast Cancer Survivor: A Guide for Primary Care Physicians
Chalasani, P., Downey, L., & Stopeck, A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.09.042 · Cited by 32
Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy
Sulaica, E. M., Han, T., Wang, W., Bhat, R. R., Trivedi, M. V., & Niravath, P. A. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3827-7 · Cited by 32
Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer
Hannouf, M. B., Zaric, G. S., Blanchette, P., Brezden‐Masley, C., Paulden, M., McCabe, C. J., Raphael, J., & Brackstone, M. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0089-x · Cited by 32
Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution’s Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer
Maranta, A. F., Broder, S., Fritzsche, C., Knauer, M., Thurlimann, B. J. K., Jochum, W., & Ruhstaller, T. (2020) · The Breast · doi:10.1016/j.breast.2020.03.005 · Cited by 33
Adjuvant Hormonal Therapy for Early-Stage Breast Cancer
Burstein, H. J., & Griggs, J. J. (2010) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2010.03.006 · Cited by 34
Managing Aromatase Inhibitors in Breast Cancer Survivors: Not Just for Oncologists
Files, J. A., Ko, M. G., & Pruthi, S. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0137 · Cited by 32
Management of breast cancer--Part I
Turner, N. C., & Jones, A. L. (2008) · BMJ · doi:10.1136/bmj.a421 · Cited by 31
Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen
Winder, T. L., Giamas, G., Wilson, P. M., Zhang, W., Yang, D., Bohanes, P. O., Ning, Y., Gerger, A., Stebbing, J., & Lenz, H. J. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.8 · Cited by 31
Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts
Andreucci, E., Francica, P., Fearns, A., Martin, L., Chiarugi, P., Isacke, C. M., & Morandi, A. (2016) · Oncotarget · doi:10.18632/oncotarget.11826 · Cited by 33
Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing
Yang, H., Crosby, M., Walker, A., Wei, D. H., Leiker, K., & Weitao, T. (2017) · Journal of Cancer · doi:10.7150/jca.22554 · Cited by 32
TCDD-induced antagonism of MEHP-mediated migration and invasion partly involves aryl hydrocarbon receptor in MCF7 breast cancer cells
Shan, A., Leng, L., Li, J., Luo, X.-M., Fan, Y.-J., Yang, Q., Xie, Q., Chen, Y., Ni, C., Guo, L.-M., et al. (2020) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2020.122869 · Cited by 31
Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy
Gallicchio, L. M., MacDonald, R., Wood, B., Rushovich, E., & Helzlsouer, K. J. (2011) · Climacteric · doi:10.3109/13697137.2011.620658 · Cited by 31
Chemoprevention for breast cancer
Božović‐Spasojević, I., de Azambuja, E., McCaskill‐Stevens, W., Dinh, P., & Cardoso, F. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.07.005 · Cited by 32
Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results
Takahashi, S., Iwase, T., Kohno, N., Ishikawa, T., Taguchi, T., Takahashi, M., Horiguchi, J., Nakamura, S., Hozumi, Y., Fukunaga, M., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-1973-0 · Cited by 31
Osteoporosis and musculoskeletal complications related to therapy of breast cancer
Suskin, J. A., & Shapiro, C. L. (2018) · Gland Surgery · doi:10.21037/gs.2018.07.05 · Cited by 32
Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)
Xu, L., Briaux, A., Becette, V., Benoist, C., Boulai, A., Chemlali, W., Schnitzler, A., Baulande, S., Rivera, S., Mouret‐Reynier, M., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0670-9 · Cited by 31
Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells
Borley, A., Hiscox, S., Gee, J. M. W., Smith, C. R., Shaw, V. E., Barrett-Lee, P. J., & Nicholson, R. I. (2008) · Breast Cancer Research · doi:10.1186/bcr2206 · Cited by 31
Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial
Cuzick, J. M., Chu, K., Keevil, B. G., Brentnall, A. R., Howell, A., Zdenkowski, N., Bonanni, B., Loibl, S., Holli, K., Evans, D. G., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00578-8 · Cited by 32
Self-citation
Safety of Adjuvant Endocrine Therapies in Hormone Receptor–Positive Early Breast Cancertissues
Sehdev, S. R., Martin, G., Sidéris, L., Lam, W., & Brisson, S. (2009) · Current Oncology · doi:10.3747/co.v16i0.457 · Cited by 30
Incidence of fractures in young women with breast cancer - a retrospective cohort study
Stumpf, U. C., Kostev, K., Kyvernitakis, I., Böcker, W., & Hadji, P. (2019) · Journal of bone oncology · doi:10.1016/j.jbo.2019.100254 · Cited by 30
Bisphosphonates: Prevention of Bone Metastases in Breast Cancer
Gnant, M., Dubsky, P. C., & Hadji, P. (2012) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-21892-7_3 · Cited by 30
ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target
Cheng, X., Zhao, J., Dong, F., & Cao, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759577 · Cited by 31
Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches
Cescon, D. W., Kalinsky, K. M., Parsons, H. A., Smith, K. L., Spears, P. A., Thomas, A., Zhao, F., & DeMichele, A. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.667397 · Cited by 31
Prophylactic mastectomy of the contralateral breast
Morrow, M. (2011) · The Breast · doi:10.1016/s0960-9776(11)70306-x · Cited by 30
Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial
Lomax, A. J., Yap, S. Y., White, K. N., Beith, J. M., Abdi, E. A., Broad, A., Sewak, S., Lee, C., Sambrook, P. N., POCOCK, N. A., et al. (2013) · Journal of bone oncology · doi:10.1016/j.jbo.2013.08.001 · Cited by 30
Neoadjuvant endocrine treatment in primary breast cancer – Review of literature
Mathew, J. M., Asgeirsson, K. S., Jackson, L. R., Cheung, K., & Robertson, J. F. R. (2009) · The Breast · doi:10.1016/j.breast.2009.09.012 · Cited by 30
Antiestrogen Use and Survival of Women with Non-small Cell Lung Cancer in Manitoba, Canada
Lother, S., Harding, G. A., Musto, G., Navaratnam, S., & Pitz, M. W. (2013) · Hormones and Cancer · doi:10.1007/s12672-013-0149-7 · Cited by 30
Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors
Lv, W., Liu, J., Skaar, T. C., O’Neill, E., Yu, G., Flockhart, D. A., & Cushman, M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01677 · Cited by 30
Safety of aromatase inhibitor therapy in breast cancer
Lintermans, A., & Neven, P. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1053458 · Cited by 29
Complementary or Alternative Medicine as Possible Determinant of Decreased Persistence to Aromatase Inhibitor Therapy among Older Women with Non-Metastatic Breast Cancer
Huiart, L., Bouhnik, A., Rey, D., Rousseau, F., Rétornaz, F., Meresse, M., Bendiane, M., Viens, P., & Giorgi, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081677 · Cited by 33
Impact of aromatase inhibitors on bone health in breast cancer patients
Geisler, J., & Lønning, P. E. (2009) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2009.10.004 · Cited by 30
Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy
Balakrishnan, A., & Ravichandran, D. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.470 · Cited by 29
Window of Opportunity trials for biomarker discovery in breast cancer
Arnedos, M., Dugage, M. R., Pérez-García, J. M., & Cortés, J. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000583 · Cited by 29
Intra-tumoural lipid composition and lymphovascular invasion in breast cancer via non-invasive magnetic resonance spectroscopy
Cheung, S. M., Husain, E. A., Mallikourti, V., Masannat, Y., Heys, S. D., & He, J. (2020) · European Radiology · doi:10.1007/s00330-020-07502-4 · Cited by 29
Quality of Life Interventions in Breast Cancer Survivors: State of the Art in Targeted Rehabilitation Strategies
Invernizzi, M., Alessandro de, S. I. R. E., Venetis, K., Cigna, E., Carda, S., Borg, M. B., Cisari, C., & Fusco, N. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210609095602 · Cited by 29
Emerging strategies to overcome resistance to endocrine therapy for breast cancer
Ziauddin, M. F., Hua, D., & Tang, S.-C. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9504-6 · Cited by 31
The Economic Consequences of Breast Cancer Adjuvant Hormonal Treatments
Pezzin, L. E., O’Niel, M. B., & Nattinger, A. B. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-009-1079-5 · Cited by 29
Current Management Strategies in Breast Cancer by Targeting Key Altered Molecular Players
Ali, S. Y., Mondal, N., Choudhry, H., Rasool, M., Pushparaj, P. N., Khan, M. A., Mahfooz, M., Sami, G. A., Jarullah, J. S., Ali, A., et al. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00045 · Cited by 31
New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus
O'Regan, R. M., & Paplomata (2013) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s30349 · Cited by 29
Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries
van Nes, J. G. H., Seynaeve, C., Jones, S., Markopoulos, C. J., Putter, H., & van de Velde, C. J. �. (2010) · British journal of surgery · doi:10.1002/bjs.6962 · Cited by 29
Aromatase inhibitors and breast cancer prevention
Litton, J. K., Arun, B., Brown, P. H., & Hortobágyi, G. N. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.651459 · Cited by 28
Induction of Integrin Signaling by Steroid Sulfatase in Human Cervical Cancer Cells
Ye, D.-J., Kwon, Y., Shin, S., Baek, H., Shin, D.-W., & Chun, Y.-J. (2016) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2016.155 · Cited by 28
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus
Untch, M., Huober, J., Jackisch, C., Schneeweiß, A., Brucker, S. Y., Dall, P., Denkert, C., Fasching, P. A., Fehm, T. N., Gerber, B., et al. (2017) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0043-111601 · Cited by 28
Breast Cancer in Women Aged 80 Years or Older: An Analysis of Treatment Patterns and Disease Outcomes
Ferrigni, E. N., Bergom, C. R., Yin, Z., Szabó, A., & Kong, A. L. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.01.007 · Cited by 28
Patterns of adjuvant care and outcomes of elderly women with stage I breast cancer after breast-conserving surgery: a population-based analysis
Goldberg, M., Sutradhar, R., Paszat, L. F., Whelan, T. J., Gu, S., Fong, C. H., & Rakovitch, E. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05266-0 · Cited by 28
Oral Health in Breast Cancer Women with Vitamin D Deficiency: A Machine Learning Study
Ferrillo, M., Migliario, M., Marotta, N., Lippi, L., Antonelli, A., Calafiore, D., Ammendolia, V., Fortunato, L., Renò, F., Giudice, A., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164662 · Cited by 28
True Recurrences and New Primary Tumors Have Different Clinical Features in Invasive Breast Cancer Patients with Ipsilateral Breast Tumor Relapse After Breast-Conserving Treatment
Yoshida, T., Takei, H., Kurosumi, M., Ninomiya, J., Ishikawa, Y., Hayashi, Y., Tozuka, K., Oba, H., Kawanowa, K., Inoue, K., et al. (2009) · The Breast Journal · doi:10.1111/j.1524-4741.2009.00884.x · Cited by 28
Adjuvant systemic therapy in breast cancer: quo vadis?
Sonnenblick, A., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv108 · Cited by 28
Skeletal health in breast cancer survivors
Bruyère, O., Bergmann, P., Cavalier, E., Gielen, E., Goemaere, S., Kaufman, J., Rozenberg, S., & Body, J. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.08.008 · Cited by 28
The endocrinology of male breast cancer
Fentiman, I. S. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0117 · Cited by 32
Breast cancer (non-metastatic).
Dixon, J. M., Gregory, K., Johnston, S. R. D., & Rodger, A. (2002) · Europe PMC (PubMed Central) · Cited by 28
Erratum to: The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom
Schmidt, N., Jacob, L., Coleman, R. E., Kostev, K., & Hadji, P. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3819-7 · Cited by 28
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II
Sestak, I., Smith, S. G., Howell, A., Forbes, J. F., & Cuzick, J. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx713 · Cited by 27
Self-citation
Risk of Cardiovascular Events and Lipid Profile Change in Patients with Breast Cancer Taking Aromatase Inhibitor: A Systematic Review and Meta-Analysis
Yoo, J., Jung, E., Kim, Z., & Kim, B. (2023) · Current Oncology · doi:10.3390/curroncol30020142 · Cited by 27
Aromatase inhibitors: the journey from the state of the art to clinical open questions
Generali, D., Berardi, R., Caruso, M., Cazzaniga, M. E., Garrone, O., Minchella, I., Paris, I., Pinto, C., & Placido, S. D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1249160 · Cited by 27
A Systematic Review and Methodological Evaluation of Published Cost-Effectiveness Analyses of Aromatase Inhibitors versus Tamoxifen in Early Stage Breast Cancer
John‐Baptiste, A., Wu, W., Rochon, P. A., Anderson, G., & Bell, C. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062614 · Cited by 27
Understanding and Optimizing Bone Health in Breast Cancer
Guise, T. A., Brufsky, A., & Coleman, R. E. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.533162 · Cited by 28
Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX ® Breast Recurrence Score Assay
Curtit, E., Mansi, L., Maisonnette-Escot, Y., Sautière, J.-L., & Pivot, X. B. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.11.016 · Cited by 27
Psychometric properties of the Beliefs about Medicine Questionnaire–adjuvant endocrine therapy (BMQ-AET) for women taking AETs following early-stage breast cancer
Brett, J., Hulbert-Williams, N., Fenlon, D., Boulton, M. G., Walter, F. M., Donnelly, P., Lavery, B. A., Morgan, A. A., Morris, C., Horne, R., et al. (2017) · Health Psychology Open · doi:10.1177/2055102917740469 · Cited by 26
Adherence to endocrine therapy among Chinese patients with breast cancer: current status and recommendations for improvement
Gao, P., You, L., Wu, D., Shi, A., Miao, Q., Rana, U., Martin, D. P., Du, Y., Zhao, G., Han, B., et al. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s167004 · Cited by 27
Pocket similarity identifies selective estrogen receptor modulators as microtubule modulators at the taxane site
Lo, Y., Cormier, O., Liu, T., Nettles, K. W., Katzenellenbogen, J. A., Stearns, T., & Altman, R. B. (2019) · Nature Communications · doi:10.1038/s41467-019-08965-w · Cited by 27
Implication of environmental estrogens on breast cancer treatment and progression
Gonzalez, T. L., Rae, J. M., & Colacino, J. A. (2019) · Toxicology · doi:10.1016/j.tox.2019.03.014 · Cited by 28
Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study
Rhee, Y., Song, K., Park, S., Park, H. S., Lim, S.-K., & Park, B. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej12-0283 · Cited by 27
Patient Adherence to Aromatase Inhibitor Treatment in the Adjuvant Setting
Verma, S., Madarnas, Y., Sehdev, S. R., Martin, G., & Bajcar, J. (2011) · Current Oncology · doi:10.3747/co.v18i0.899 · Cited by 27
Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation
Sikora, M. J., Strumba, V., Lippman, M. E., Johnson, M. D., & Rae, J. M. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2032-6 · Cited by 27
Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer.
Ishitobi, M., Komoike, Y., Motomura, K., Koyama, H., Nishiyama, K., & Inaji, H. (2009) · PubMed · Cited by 27
Different Annual Recurrence Pattern Between Lumpectomy and Mastectomy: Implication for Breast Cancer Surveillance After Breast-Conserving Surgery
Yu, K., Li, S., & Shao, Z. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0366 · Cited by 27
Overview of long term care of breast cancer survivors
Brennan, M. E., & Houssami, N. (2011) · Maturitas · doi:10.1016/j.maturitas.2011.03.010 · Cited by 27
Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer
Strasser‐Weippl, K., Badovinac-Črnjević, T., Fan, L., & Goss, P. E. (2013) · The Breast · doi:10.1016/j.breast.2013.07.033 · Cited by 26
The Difference in Prognostic Factors between Early Recurrence and Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Nodal Stage Differently Impacts Early and Late Recurrence
Ahn, S. G., Lee, H. M., Cho, S.-H., Bae, S. J., Lee, S. A., Hwang, S. H., Jeong, J., & Lee, H.-D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063510 · Cited by 26
The skeletal impact of cancer therapies
Bedatsova, L., & Drake, M. T. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13866 · Cited by 26
Surveillance for second breast cancer events in women with a personal history of breast cancer using breast MRI: a systematic review and meta-analysis
Haas, C. B., Nekhlyudov, L., Lee, J. M., Javid, S. H., Bush, M., Johnson, D., Gleason, T., Kaufman, C. S., Specht, J. M., Stitham, S., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05637-y · Cited by 26
How we Treat HR-Positive, HER2-Negative Early Breast Cancer
López‐Tarruella, S., Echavarría, I., Jerez, Y., Herrero, B., Casado, S. G., & Martín, M. (2022) · Future Oncology · doi:10.2217/fon-2021-0668 · Cited by 29
How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review
Royle, K., Meads, D. M., Visser‐Rogers, J. K., White, I. R., & Cairns, D. A. (2023) · Trials · doi:10.1186/s13063-023-07730-1 · Cited by 28
Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer
Lin, M.-L., Patel, H., Reményi, J., Banerji, C. R. S., Lai, C., Periyasamy, M., Lombardo, Y., Busonero, C., Ottaviani, S., Passey, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3942 · Cited by 26
Cost‐effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population
Noah‐Vanhoucke, J., Green, L. E., Dinh, T., Alperin, P., & Smith, R. A. (2011) · Cancer · doi:10.1002/cncr.25926 · Cited by 26
Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
Bauer, M., Bryce, J., & Hadji (2012) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s29432 · Cited by 25
Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes
Cronin-Fenton, D. P., & Lash, T. L. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.18 · Cited by 25
A UK national survey of breast surgeons on primary endocrine therapy of early operable breast cancer
Wylie, S., & Ravichandran, D. (2013) · Annals of The Royal College of Surgeons of England · doi:10.1308/003588413x13629960045832 · Cited by 26
2008 Santa Fe Bone Symposium: Update on Osteoporosis
Lewiecki, E. M., Baim, S., Bilezikian, J. P., Eastell, R., LeBoff, M. S., & Miller, P. D. (2009) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2009.02.002 · Cited by 26
Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial
Xu, B., Jiang, Z., Shao, Z., Wang, J., Feng, J., Song, S., Chen, Z., Gu, K., Yu, S., Zhang, Y., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1483-x · Cited by 26
Comparison of Adjuvant Radiation Therapy Alone Versus Radiation Therapy and Endocrine Therapy in Elderly Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Treated With Breast-Conserving Surgery
Murphy, C. T., Li, T., Wang, L. S., Obeid, E. I., Bleicher, R. J., Eastwick, G. A., Johnson, M. E., Hayes, S. B., Weiss, S. E., & Anderson, P. R. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.02.005 · Cited by 27
Changes to Adjuvant Systemic Therapy in Breast Cancer: A Decade in Review
Saurel, C. A., Patel, T. A., & Perez, E. A. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.027 · Cited by 26
Hormone therapy in elderly breast cancer patients with comorbidities
Crivellari, D., Spazzapan, S., Puglisi, F., Fratino, L., Scalone, S., & Veronesi, A. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.02.003 · Cited by 27
The Protective Effect of Zoledronic Acid on Bone Loss in Postmenopausal Women with Early Breast Cancer Treated with Sequential Tamoxifen and Letrozole: A Prospective, Randomized, Phase II Trial
Safra, T., Bernstein‐Molho, R., Greenberg, J., Pelles-Avraham, S., Stephansky, I., Sarid, D. L., Inbar, M., Stemmer, S. M., & Geffen, D. B. (2011) · Oncology · doi:10.1159/000334456 · Cited by 26
Exemestane for Breast Cancer Prevention: A Critical Shift?
DeCensi, A., Dunn, B. K., Puntoni, M., Gennari, A., & Ford, L. G. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0248 · Cited by 26
Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer
Cuzick, J. M. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv392 · Cited by 27
Self-citation
Increased risk of colorectal cancer in patients diagnosed with breast cancer in women
Lu, Y., Segelman, J., Nordgren, A., Lindström, L., Frisell, J., & Martling, A. (2016) · Cancer Epidemiology · doi:10.1016/j.canep.2016.01.006 · Cited by 26
Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study
Moncusí, M. P., Servitja, S., Tusquets, I., Díez‐Pérez, A., Rial, A., Cos, M. L., Campodarve, I., Rodríguez‐Morera, J., García‐Giralt, N., & Nogués, X. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05289-7 · Cited by 26
Preventative therapies for healthy women at high risk of breast cancer
Šestak, I. (2014) · Cancer Management and Research · doi:10.2147/cmar.s55219 · Cited by 26
Aromatase Inhibitor-Associated Bone Loss
Pant, S., & Shapiro, C. L. (2008) · Drugs · doi:10.2165/0003495-200868180-00005 · Cited by 27
Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index
Şendur, M. A. N., Aksoy, S., Zengin, N., & Altundağ, K. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.473 · Cited by 25
Reconstruction mammaire immédiate après mastectomie suivie de radiothérapie : facteurs de risque de complications
Groß, E., Hannoun‐Lévi, J., Rouanet, P., Houvenaeghel, G. F., Teissier, E., Ellis, S. B., Resbeut, M., Tallet, A. R., Cowen, V. V., Azria, D., et al. (2010) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2010.05.004 · Cited by 25
Low Adherence to Upfront and Extended Adjuvant Letrozole Therapy among Early Breast Cancer Patients in a Clinical Practice Setting
Lee, H. S., Lee, J., Ah, Y.-M., Kim, H. S., Im, S., Noh, D., & Lee, B. K. (2014) · Oncology · doi:10.1159/000360702 · Cited by 26
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer
Grzywacz, M., & Yardley, D. A. (2016) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s97963 · Cited by 25

Authors: Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F.
Affiliations: University of London (GB)
Cancer Research UK (GB)
The University of Texas MD Anderson Cancer Center (US)
Royal Marsden Hospital (GB)
University of Newcastle Australia (AU)
Corresponding author: Cuzick, Jack
ORCID: Cuzick, Jack
Baum, Michael
Buzdar, Aman
Howell, Anthony
Dowsett, Mitch
Forbes, John F
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2010-12
Volume: 11
Issue: 12
Pages: 1135-1141
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(10)70257-6
OpenAlex: W2112780046
Cited by: 1,674
References: 27
Citations by year: 2026: 21 · 2025: 35 · 2024: 50 · 2023: 54 · 2022: 63 · 2021: 64 · 2020: 85 · 2019: 66 · 2018: 85 · 2017: 98 · 2016: 101 · 2015: 116 · 2014: 125 · 2013: 148 · 2012: 121
FWCI: 51.63
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Research Explorer (The University of Manchester) (submittedVersion)
NOVA (University of Newcastle Australia) (submittedVersion)
Funders: AstraZeneca
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Keywords: anastrozole, tamoxifen, adjuvant endocrine therapy, early breast cancer, postmenopausal women, disease-free survival, time to recurrence, distant recurrence, hormone receptor-positive breast cancer, contralateral breast cancer, overall survival, fracture risk, long-term outcomes, ATAC trial, aromatase inhibitors, selective estrogen receptor modulators, breast cancer recurrence
MeSH terms: Anastrozole, Administration, Oral, Breast Neoplasms, Female, Follow-Up Studies, Humans, Neoplasm Staging, Nitriles, Tamoxifen, Triazoles, Treatment Outcome, Chemotherapy, Adjuvant, Postmenopause, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks